Journal of Neural Transmission

, Volume 113, Issue 11, pp 1771–1778

CSF diagnosis of Alzheimer’s disease and dementia with Lewy bodies

  • M. Bibl
  • B. Mollenhauer
  • H. Esselmann
  • P. Lewczuk
  • C. Trenkwalder
  • P. Brechlin
  • E. Rüther
  • J. Kornhuber
  • M. Otto
  • J. Wiltfang
Article

DOI: 10.1007/s00702-006-0537-z

Cite this article as:
Bibl, M., Mollenhauer, B., Esselmann, H. et al. J Neural Transm (2006) 113: 1771. doi:10.1007/s00702-006-0537-z

Summary.

Differential diagnosis of Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) is often crucial. CSF Tau protein and Amyloid-beta (Aβ) peptides have shown diagnostic value for the diagnosis of AD, but discrimination from DLB was poor.

Herein, we investigate CSF of 18 patients with probable AD, 25 with probable DLB and 14 non-demented disease controls (NDC) by Aβ-SDS-PAGE/immunoblot and commercially available ELISAs for Aβ1-42 and tau. CSF Aβ peptide patterns and tau exhibited disease specific alterations among AD and DLB. The ratio of Aβ1-42 to Aβ1-38 and Aβ1-42 to Aβ1-37, respectively, in combination with absolute tau, yielded a sensitivity and specificity of 100 and 92%, respectively. We conclude that CSF Aβ peptide patterns and tau levels reflect disease-specific pathophysiological pathways of these dementias as distinct neurochemical phenotypes. Combined evaluation of these biomarkers provides a reasonable accuracy for differential diagnosis of AD and DLB.

Keywords: Alzheimer’s dementia, Lewy-body dementia, cerebrospinal fluid, amyloid-β peptides, tau protein, biomarker

Abbreviations:

Aβ peptides

amyloid-beta peptides

Aβ-SDS-PAGE/immunoblot

amyloid-beta-sodium-dodecyl-sulphate-polyacrylamide-gel-electrophoresis with western immunoblot

AD

Alzheimer’s disease

ApoE ɛ4

apolipoprotein E allele ɛ4

APP

beta-amyloid precursor protein

bicine

N,N′-bis-[2-hydroxyethyl]glycine

CCD-camera

charge coupled device camera

CSF

cerebrospinal fluid

Ct-elongated

carboxyterminally elongated

Ct-truncated

carboxyterminally truncated

DLB

dementia with Lewy bodies

ECL

enhanced chemiluminescence

ELISA

Enzyme Linked Immunosorbent Assay

MMSE

Mini-Mental-Status Examination

NINCDS-ADRDA

National Institute Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association

ND

non-demented

PDD

Parkinson’s disease dementia

PVDF

polyvinylidene difluoride

SDS

sodium dodecyl sulphate

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • M. Bibl
    • 1
  • B. Mollenhauer
    • 2
  • H. Esselmann
    • 3
  • P. Lewczuk
    • 3
  • C. Trenkwalder
    • 4
  • P. Brechlin
    • 1
  • E. Rüther
    • 1
  • J. Kornhuber
    • 3
  • M. Otto
    • 5
  • J. Wiltfang
    • 3
  1. 1.Department of PsychiatryUniversity of GoettingenGoettingenGermany
  2. 2.Brigham and Women’s Hospital, Center for Neurologic DiseasesHarvard Medical SchoolBostonUSA
  3. 3.Department of Psychiatry and PsychotherapyUniversity of Erlangen-NurembergErlangenGermany
  4. 4.University of GoettingenParacelsus-Elena KlinikGermany
  5. 5.Department of NeurologyUniversity of UlmGermany